Elranatamab for high-risk smoldering multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called Elranatamab for people with a high-risk form of smoldering multiple myeloma (SMM). The goal is to see if the drug can prevent or delay the progression to active multiple myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with smoldering multiple myeloma for 5 years or less, with signs of the disease in your blood or urine.
- You have at least 2 high-risk features, such as a high level of M protein, more than 20% plasma cells in your bone marrow, or an abnormal ratio of light chains in your blood.
- You are in good physical condition (ECOG score 0 or 1), meaning you can carry out daily activities without help.
- Your blood cell counts and organ function are within safe limits.
- You have not received any prior treatment for multiple myeloma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
This Phase 1 trial tests belantamab mafodotin, a cancer medicine, in people with high-risk smoldering multiple myeloma to see how safe it is and whether it may shrink or control the disease. Because it’s an early-stage study, you would be closely monitored and treated with one main study drug.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This trial tests a combination of four drugs (elranatamab, isatuximab, bortezomib, and lenalidomide) for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this combination is safe and effective.
This trial tests a new medicine called a BCMA/CD3 bispecific antibody for people with a very early form of multiple myeloma called high-risk smoldering myeloma. The goal is to see if this treatment can stop the disease from getting worse.
Hear when a new Smoldering Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.